<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981639</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0032</org_study_id>
    <nct_id>NCT04981639</nct_id>
  </id_info>
  <brief_title>TAP and IMS for HIPEC</brief_title>
  <official_title>Effects of Transabdominal Plane Block and Electrical Twitch Obtaining Intramuscular Stimulation on the Postoperative Pain in Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (CRS and HIPEC): a Double-blind Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is important to decrease the postoperative pain in patients undergoing cytoreductive&#xD;
      surgery and hyperthermic intra-peritoneal chemotherapy. We will compare the Transversus&#xD;
      abdominis plane block with the Transversus abdominis plane block plus intramuscular&#xD;
      electrical stimulation in patients undergoing cytoreductive surgery and hyperthermic&#xD;
      intra-peritoneal chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 22, 2021</start_date>
  <completion_date type="Anticipated">August 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>At postoperative day 1</time_frame>
    <description>Pain score will be measured using visual analogue scale (0: no pain, 10: worst imaginable pain) at postoperative day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>At postoperative day 2, 3, 5, 7, 14 and 28</time_frame>
    <description>Pain score will be measured using visual analogue scale (0: no pain, 10: worst imaginable pain) at postoperative day 0, 2, 3, 5, 7, 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVPCA consumption</measure>
    <time_frame>At postoperative day 1, 2, and 3</time_frame>
    <description>Intravenous patient controlled analgesia consumption will be measured at postoperative day 0, 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea will be evaluated using 2 point scale (yes, no)</measure>
    <time_frame>At postoperative day 1, 2, 3, 5 and 7</time_frame>
    <description>Nausea will be evaluated using 2 point scale (yes, no) at postoperative day 1, 2, 3, 5 and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting will be evaluated using 2 point scale (yes, no)</measure>
    <time_frame>at postoperative day 1, 2, 3, 5 and 7.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak cough flow</measure>
    <time_frame>At postoperative day -1, 4, 7, 14, and 28</time_frame>
    <description>Peak cough flow will be evaluated at postoperative day -1, 4, 7, 14, and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait speed</measure>
    <time_frame>day -1, 4, 7, 14, and 28</time_frame>
    <description>Gait speed will be evaluated at postoperative day -1, 4, 7, 14, and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be evaluated using QoR40 questionnaire (0-200)</measure>
    <time_frame>At postoperative day 4 and 7</time_frame>
    <description>Quality of life will be evaluated using QoR40 questionnaire (0-200) at postoperative day 4 and 7.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Cytoreductive Surgery</condition>
  <arm_group>
    <arm_group_label>I (IVPCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous patient controlled analgesia will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II (IVPCA+TAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III (IVPCA, IMS, and TAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVPCA</intervention_name>
    <description>Intravenous patient controlled analgesia will be performed.</description>
    <arm_group_label>I (IVPCA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP</intervention_name>
    <description>Transversus abdominis plane block will be performed.</description>
    <arm_group_label>II (IVPCA+TAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IMS</intervention_name>
    <description>Intramuscular electrical stimulation will be performed.</description>
    <arm_group_label>III (IVPCA, IMS, and TAP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Patients who are able to do daily activity and walk independently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of preoperative abdominal surgery&#xD;
&#xD;
          2. Patients who are unable to walk independently due to musculoskeletal disorder&#xD;
&#xD;
          3. Patients who are allergic to local anesthetics&#xD;
&#xD;
          4. Patients with chronic pain&#xD;
&#xD;
          5. Patients with pacemaker&#xD;
&#xD;
          6. Patients with endotracheal tube postoperatively&#xD;
&#xD;
          7. Patients with history of substance abuse&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Patients who are unable to communicate due to mental disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyung Chang Kim</last_name>
    <phone>82-2-2019-4601</phone>
    <email>ONIDORI@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangnamSeveranceHospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Song</last_name>
      <phone>82-2-2019-4601</phone>
    </contact>
    <contact_backup>
      <last_name>Hyun Chang Kim</last_name>
      <phone>82-2-2019-4601</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Young Song</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hyperthermic intra-peritoneal chemotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

